Safety Study Of SNX-5422 To Treat Solid Tumor Cancers And Lymphomas

Phase 1 Study Of SNX-5422 Mesylate In Adults With Refractory Solid Tumor Malignancies And Lymphomas

Hsp90 is a chemical in the body that is involved in promotion of cancer. SNX-5422 is an experimental drug that blocks Hsp90. It is being evaluated for safety and efficacy in patients with cancer.

Inclusion Criteria:

• Solid tumors or lymphoid malignancies refractory to standard therapy
• measurable disease
• recovery to Grade < 1 toxicity due to prior adverse event or chemotherapy
• no chemotherapy within 4 weeks of entering study
• Age > 18 years
• Karnofsy >= 60%
• Life expectancy > 3 months
• normal or adequate organ and marrow function

Exclusion Criteria:

• receiving other investigational agents
• brain metastases
• uncontrolled medical illness
• HIV+ receiving combination antiretroviral therapy
• significant GI disease